Kiniksa Pharmaceuticals (NASDAQ:KNSA) Downgraded by ValuEngine to Hold

ValuEngine lowered shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) from a buy rating to a hold rating in a research note issued to investors on Thursday morning, ValuEngine reports.

KNSA has been the topic of a number of other reports. BidaskClub upgraded shares of Kiniksa Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, February 5th. Goldman Sachs Group upgraded shares of Kiniksa Pharmaceuticals from a neutral rating to a buy rating and upped their target price for the stock from $16.00 to $18.00 in a research note on Friday, December 6th. Finally, Zacks Investment Research upgraded shares of Kiniksa Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, February 5th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Kiniksa Pharmaceuticals presently has an average rating of Buy and a consensus price target of $21.75.

KNSA stock traded down $0.93 during mid-day trading on Thursday, reaching $17.33. The company had a trading volume of 232,951 shares, compared to its average volume of 244,655. The company has a market capitalization of $970.24 million, a PE ratio of -5.22 and a beta of -1.06. The firm has a 50 day moving average of $14.48 and a 200 day moving average of $10.48. Kiniksa Pharmaceuticals has a 12 month low of $5.01 and a 12 month high of $21.50.

A number of hedge funds have recently modified their holdings of KNSA. Citigroup Inc. boosted its stake in shares of Kiniksa Pharmaceuticals by 138.2% during the fourth quarter. Citigroup Inc. now owns 2,797 shares of the company’s stock valued at $31,000 after purchasing an additional 1,623 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Kiniksa Pharmaceuticals by 22,613.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,814 shares of the company’s stock valued at $76,000 after purchasing an additional 6,784 shares in the last quarter. California Public Employees Retirement System bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $111,000. Quantitative Systematic Strategies LLC bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $133,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $144,000. Institutional investors and hedge funds own 29.87% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Further Reading: How Investors Can Profit from Options Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.